open access

Vol 19, No 1 (2016)
Case Report
Published online: 2016-01-29
Submitted: 2015-05-14
Accepted: 2015-12-18
Get Citation

Problems of diagnostic assessment in advanced pancreatic neuroendocrine neoplasm and treatment implications: a case report and literature review

Bartosz Szymanowski, Renata Duchnowska, Marek Bilski, Grażyna Łapińska, Beata Hryciuk, Grzegorz Kamiński, Cezary Szczylik
DOI: 10.5603/NMR.2016.0011
·
Pubmed: 26838946
·
Nucl. Med. Rev 2016;19(1):54-57.

open access

Vol 19, No 1 (2016)
Case Report
Published online: 2016-01-29
Submitted: 2015-05-14
Accepted: 2015-12-18

Abstract

We are reporting a case of a 55-year-old woman who was diagnosed as having a non-functioning pancreatic neuroendocrine neoplasm (NF-PNEN), the World Health Organization (WHO) low grade (G1) with liver metastases. In the staging process the positron emission tomography — computed tomography with Fluorine-18-Fluorodeoxyglucose (F-FDG PET-CT) and spiral CT then the gallium-DOTA-octreotate positron emission tomography — computer tomography (68Ga-DOTATATE PET-CT) shown difference in burden of disease. In first line therapy, everolimus (Afinitor®, Novartis Pharma GmbH, Germany) at the oral dose of 10 mg once daily and octreotide long-acting release (Sandostatin LAR®) 30 mg i.m. every 4 weeks were administered. Then, due to disease progression — radioisotope therapy with b-emitter Yttrium-90 (90Y). Based on this experience and on the review of the literature, we recommend that the discrepancy between the imaging studies could be due to heterogeneity of proliferation rate and somatostatin receptors (SSTR) expression within a primary PNEN and metastases. Therefore in such cases of advanced PNEN WHO G1 in the lack of response to everolimus and octreotide LAR administration isotope therapy without a prior chemotherapy should be considered as a palliative treatment according to ESMO Clinical Practice Guidelines and Polish Network of Neuroendocrine Tumors.

Abstract

We are reporting a case of a 55-year-old woman who was diagnosed as having a non-functioning pancreatic neuroendocrine neoplasm (NF-PNEN), the World Health Organization (WHO) low grade (G1) with liver metastases. In the staging process the positron emission tomography — computed tomography with Fluorine-18-Fluorodeoxyglucose (F-FDG PET-CT) and spiral CT then the gallium-DOTA-octreotate positron emission tomography — computer tomography (68Ga-DOTATATE PET-CT) shown difference in burden of disease. In first line therapy, everolimus (Afinitor®, Novartis Pharma GmbH, Germany) at the oral dose of 10 mg once daily and octreotide long-acting release (Sandostatin LAR®) 30 mg i.m. every 4 weeks were administered. Then, due to disease progression — radioisotope therapy with b-emitter Yttrium-90 (90Y). Based on this experience and on the review of the literature, we recommend that the discrepancy between the imaging studies could be due to heterogeneity of proliferation rate and somatostatin receptors (SSTR) expression within a primary PNEN and metastases. Therefore in such cases of advanced PNEN WHO G1 in the lack of response to everolimus and octreotide LAR administration isotope therapy without a prior chemotherapy should be considered as a palliative treatment according to ESMO Clinical Practice Guidelines and Polish Network of Neuroendocrine Tumors.

Get Citation

Keywords

68Ga-DOTATATE PET-CT, pancreatic neuroendocrine neoplasms, everolimus, octreotide

About this article
Title

Problems of diagnostic assessment in advanced pancreatic neuroendocrine neoplasm and treatment implications: a case report and literature review

Journal

Nuclear Medicine Review

Issue

Vol 19, No 1 (2016)

Pages

54-57

Published online

2016-01-29

DOI

10.5603/NMR.2016.0011

Pubmed

26838946

Bibliographic record

Nucl. Med. Rev 2016;19(1):54-57.

Keywords

68Ga-DOTATATE PET-CT
pancreatic neuroendocrine neoplasms
everolimus
octreotide

Authors

Bartosz Szymanowski
Renata Duchnowska
Marek Bilski
Grażyna Łapińska
Beata Hryciuk
Grzegorz Kamiński
Cezary Szczylik

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl